Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 562 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Radiographic Examination Clear all

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
Interventions: Bintrafusp alfa/M7824, Ibuprofen, PET scan, CT scan, Tumor tissue biopsy, Brain MRI, Dotate scan, PET FDG scan, Nuclear bone scan, EKG; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Behavior, Process, Acceptance, Inertia of Accommodation
Interventions: targetted implementation strategies; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer Screening
Interventions: COLON Capsule endoscopy, Computed Tomographic Colonography; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Mobile, Alabama • Jacksonville, Florida • Chicago, Illinois + 8 more

Conditions: Metabolic Syndrome
Interventions: intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Recurrent Multiple Myeloma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease, Ischemia
Interventions: Computed Tomography Angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer
Interventions: Biograph Vision Quadra scanner, PET/CT; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Prostate Cancer
Interventions: [68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT; Drug · Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions: CT scan; Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer Disease, White Matter Hyperintensities, Dementia, Aging
Interventions: Florbetaben F18, Transcranial Doppler; Radiation · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Computed Tomography; Device
Lead sponsor: Koning Corporation; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Aerobic Exercise, Exercise Intervention, Educational Intervention, Dual X-ray Absorptiometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing, Physical Performance Testing, Questionnaire Administration, Biospecimen Collection, Pulmonary Function Test; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: 18F-rhPSMA-7.3, PET/CT; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bile Duct Strictures, Common Bile Duct Stones
Interventions: ERCP with cholangioscopy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • Tampa, Florida + 2 more

Conditions: Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions: Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR); Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: METASTATIC BREAST CANCER
Interventions: Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biospecimen Collection, Dual X-ray Absorptiometry; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 30 Years to 80 Years · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Shoulder Dislocation
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Fresno, California

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Implementation of Ultrasound Guided Central Venous Catheter Confirmation Protocol

Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.

Insulin Sensitivity in Men With the Metabolic Syndrome

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

A Study of a New PET Scanner in People With Cancer

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

Brain Vascular Disease in Aging and Dementia

Cone Beam Computed Tomography for Breast Imaging

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Bone Loss in Melanoma Survivors Receiving Immunotherapy

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

Anterior Shoulder Dislocation